Breaking News, Collaborations & Alliances

PhoreMost, Otsuka Enter Drug Discovery Alliance

Will leverage PhoreMost’s phenotypic screening platform, SITESEEKER, to identify novel targets for Otsuka’s discovery programs

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

PhoreMost Ltd., a UK-based biopharma company dedicated to drugging ‘undruggable’ disease targets, has entered into a multi-project collaboration with Otsuka Pharmaceutical Co. Financial details were not disclosed. PhoreMost will leverage its expertise and next-gen phenotypic screening platform, SITESEEKER, for disease relevant pathways selected by Otsuka. Novel targets identified will be further validated and characterized by Otsuka as part of its development pipeline, with an initial focus ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters